

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 69365

**Title:** Single dose dexamethasone prophylaxis of postembolisation syndrome after transcatheter arterial chemoembolisation in hepatocellular carcinoma patient: a randomised, double-blind, placebo-controlled study

**Reviewer's code:** 00032020

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Thailand

**Manuscript submission date:** 2021-07-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-07-05 00:13

**Reviewer performed review:** 2021-07-06 07:23

**Review time:** 1 Day and 7 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

Manuscript NO: 69365 Title: Single dose dexamethasone prophylaxis of postembolisation syndrome after transcatheter arterial chemoembolisation: a randomised, double-blind, placebo-controlled study Manuscript Type: Clinical Trials Study Correspondence to: Sakkarin Chirapongsathorn, MD, MSc This was the well-designed prospective randomized study. Some queries were left in the backgrounds and the study setting. I understood the patients' care during TACE. The conventional on demand therapy was useful for patients after TACE. Was it necessary to use steroids for prevention of PES? The present study allowed the administration of antipyretic or anti-emetic drug to patients in both groups. Such drugs could modify the SWOG score. This was a critical problem in the present study. The evaluation point was not clear; for 48 hours or after seven days? Author should mention it clearly. I wondered that single dose dexamethasone delayed the occurrence of PES. How about it? Table 2 showed that tumor size > 3cm was independent risk for development of PES syndrome. How about number of patients with tumor size > 3cm in dexamethasone and placebo groups? Table 1 showed that median tumor size was greater in placebo group than those in dexamethasone group. Authors should add the additional data in Table. In the refereed paper 12, patients with DM were excluded from the study. On the hand, patients with DM were enrolled into the present study. How about serum glucose level in dexamethasone group?

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 69365

**Title:** Single dose dexamethasone prophylaxis of postembolisation syndrome after transcatheter arterial chemoembolisation in hepatocellular carcinoma patient: a randomised, double-blind, placebo-controlled study

**Reviewer's code:** 00032020

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Thailand

**Manuscript submission date:** 2021-07-04

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2021-08-03 06:00

**Reviewer performed review:** 2021-08-05 02:30

**Review time:** 1 Day and 20 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

Manuscript NO: 69365 Title: Single dose dexamethasone prophylaxis of postembolisation syndrome after transcatheter arterial chemoembolisation: a randomised, double-blind, placebo-controlled study Manuscript Type: Clinical Trials Study Correspondence to: Sakkarin Chirapongsathorn, MD, MSc Thank you for polite response to my queries. I am satisfied with revision except one issue. The below limitation should be added into Discussion; After observation period, 48 hours, adverse events were not evaluated in both groups.